Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11770355 | 0.86 | NQO1 (0.47) | APPTDP1TSHRMAOBKDM4E | |
| SCHEMBL5824848 | 0.80 | CA12 (0.52) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2414300 | 0.80 | MAPT (0.56) | CA1CA2CA7CA9CA12 | |
| SCHEMBL6690641 | 0.80 | APP (0.53) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3084832 | 0.79 | LMNA (0.48) | ACHETDP1MAPTL3MBTL1NPSR1 | |
| SCHEMBL1148163 | 0.79 | NQO1 (0.74) | CA1CA2CA7CA9CA12 | |
| SCHEMBL5660131 | 0.78 | MAPT (0.59) | CA1CA2CA7CA9CA12 | |
| SCHEMBL1343630 | 0.78 | CA12 (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10637391 | 0.78 | CA1 (0.65) | CA1CA2CA7CA9CA12 | |
| 1,4-Dimethoxybenzene SCHEMBL8489 | 0.76 | CA1 (1.00) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190047939-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF 17(20)-ENE B-SECO STEROIDS | PATHEON AUSTRIA GMBH & CO KG (AU) | 2019-02-14 | — | — | US | disclosed |
| CN-109219612-A | Prepare 17 (20)-alkene B- open loop steroids method and intermediate | 帕西昂奥地利有限两合公司 | 2019-01-15 | — | — | CN | disclosed |
| EP-3423465-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF 17(20)-ENE B-SECO STEROIDS | Patheon Austria GmbH & Co KG (AT) | 2019-01-09 | — | — | EP | disclosed |
| WO-2017031209-A1 | TUBULYSIN ANALOGS AND METHODS | ENDOCYTE, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20030181742-A1 | Process for the preparation of pregnane derivatives | KURARAY CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1325928-A1 | PROCESS FOR THE PREPARATION OF PREGNANE DERIVATIVES | Kuraray Co., Ltd. (JP) | 2003-07-09 | — | — | EP | disclosed |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | disclosed |
| WO-2002081441-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRROLIDINE NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-0711773-B1 | HYMENIALDISINE AND DERIVATIVE THEREOF, PROCESS FOR PRODUCING INTERMEDIATE FOR SYNTHESIZING THE SAME, AND SAID INTERMEDIATE | SUNTORY LTD (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-5621099-A | CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0711773-A1 | HYMENIALDISINE AND DERIVATIVE THEREOF, PROCESS FOR PRODUCING INTERMEDIATE FOR SYNTHESIZING THE SAME, AND SAID INTERMEDIATE | SUNTORY LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
| US-4835312-A | Production process of N-substituted amide compounds | MITSUI CHEMICALS, INCORPORATED (JP) | 1989-05-30 | — | — | US | disclosed |
| US-4124765-A | ANTITUMOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 1978-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047939-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF 17(20)-ENE B-SECO STEROIDS | CYP17A1, CYP46A1, HSD17B7 | CA1 2901/4885CA2 3802/4885CA7 1682/4885 |
| US-20030181742-A1 | Process for the preparation of pregnane derivatives | CYP21A2, CYP11B2, CYP17A1 | CA1 295/4885CA2 385/4885CA7 335/4885 |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | NEU4, NEU2, NEU1 | CA1 2839/4885CA2 2385/4885CA7 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.